Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Stable liquid glucagon formulations for rescue treatment and bi-hormonal closed-loop pancreas.

Jackson MA, Caputo N, Castle JR, David LL, Roberts CT Jr, Ward WK.

Curr Diab Rep. 2012 Dec;12(6):705-10. doi: 10.1007/s11892-012-0320-5. Review.

2.

A novel, stable, aqueous glucagon formulation using ferulic acid as an excipient.

Bakhtiani PA, Caputo N, Castle JR, El Youssef J, Carroll JM, David LL, Roberts CT Jr, Ward WK.

J Diabetes Sci Technol. 2015 Jan;9(1):17-23. doi: 10.1177/1932296814552476. Epub 2014 Sep 24.

3.

Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.

Haidar A, Legault L, Messier V, Mitre TM, Leroux C, Rabasa-Lhoret R.

Lancet Diabetes Endocrinol. 2015 Jan;3(1):17-26. doi: 10.1016/S2213-8587(14)70226-8. Epub 2014 Nov 27.

PMID:
25434967
4.

Development of a fully automated closed loop artificial pancreas control system with dual pump delivery of insulin and glucagon.

Jacobs PG, El Youssef J, Castle JR, Engle JM, Branigan DL, Johnson P, Massoud R, Kamath A, Ward WK.

Conf Proc IEEE Eng Med Biol Soc. 2011;2011:397-400. doi: 10.1109/IEMBS.2011.6090127.

PMID:
22254332
5.

A review of artificial pancreas technologies with an emphasis on bi-hormonal therapy.

Bakhtiani PA, Zhao LM, El Youssef J, Castle JR, Ward WK.

Diabetes Obes Metab. 2013 Dec;15(12):1065-70. doi: 10.1111/dom.12107. Epub 2013 Apr 21. Review.

6.

Development of stable liquid glucagon formulations for use in artificial pancreas.

Pohl R, Li M, Krasner A, De Souza E.

J Diabetes Sci Technol. 2015 Jan;9(1):8-16. doi: 10.1177/1932296814555541. Epub 2014 Oct 28.

7.

Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes.

Haymond MW, Schreiner B.

Diabetes Care. 2001 Apr;24(4):643-5.

PMID:
11315823
8.

Pharmacokinetics modeling of exogenous glucagon in type 1 diabetes mellitus patients.

Lv D, Breton MD, Farhy LS.

Diabetes Technol Ther. 2013 Nov;15(11):935-41. doi: 10.1089/dia.2013.0150. Epub 2013 Aug 26.

9.

Mechanisms of glucagon degradation at alkaline pH.

Caputo N, Castle JR, Bergstrom CP, Carroll JM, Bakhtiani PA, Jackson MA, Roberts CT Jr, David LL, Ward WK.

Peptides. 2013 Jul;45:40-7. doi: 10.1016/j.peptides.2013.04.005. Epub 2013 May 4.

10.

Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial.

Haidar A, Legault L, Matteau-Pelletier L, Messier V, Dallaire M, Ladouceur M, Rabasa-Lhoret R.

Lancet Diabetes Endocrinol. 2015 Aug;3(8):595-604. doi: 10.1016/S2213-8587(15)00141-2. Epub 2015 Jun 8.

PMID:
26066705
11.

Biochemical stabilization of glucagon at alkaline pH.

Caputo N, Jackson MA, Castle JR, El Youssef J, Bakhtiani PA, Bergstrom CP, Carroll JM, Breen ME, Leonard GL, David LL, Roberts CT Jr, Ward WK.

Diabetes Technol Ther. 2014 Nov;16(11):747-58. doi: 10.1089/dia.2014.0047. Epub 2014 Jun 26.

12.

Diabetes: Artificial pancreas--first head-to-head comparison of dual-hormone and single-hormone systems.

Holmes D.

Nat Rev Endocrinol. 2015 Feb;11(2):63. doi: 10.1038/nrendo.2014.221. Epub 2014 Dec 16. No abstract available.

PMID:
25511314
13.

Multicenter outpatient dinner/overnight reduction of hypoglycemia and increased time of glucose in target with a wearable artificial pancreas using modular model predictive control in adults with type 1 diabetes.

Del Favero S, Place J, Kropff J, Messori M, Keith-Hynes P, Visentin R, Monaro M, Galasso S, Boscari F, Toffanin C, Di Palma F, Lanzola G, Scarpellini S, Farret A, Kovatchev B, Avogaro A, Bruttomesso D, Magni L, DeVries JH, Cobelli C, Renard E; AP@home Consortium..

Diabetes Obes Metab. 2015 May;17(5):468-76. doi: 10.1111/dom.12440. Epub 2015 Feb 16.

PMID:
25600304
14.
15.

Artificial pancreas: fuzzy logic and control of glycemia.

Nimri R, Phillip M.

Curr Opin Endocrinol Diabetes Obes. 2014 Aug;21(4):251-6. doi: 10.1097/MED.0000000000000073. Review.

PMID:
24937038
16.

Glucagon stimulates hepatic FGF21 secretion through a PKA- and EPAC-dependent posttranscriptional mechanism.

Cyphert HA, Alonge KM, Ippagunta SM, Hillgartner FB.

PLoS One. 2014 Apr 14;9(4):e94996. doi: 10.1371/journal.pone.0094996. eCollection 2014.

17.

Improvement in blunted glucagon response to insulin-induced hypoglycemia by strict glycemic control in diabetics.

Katsura M, Kawamori R, Yamasaki Y, Iwama N, Kubota M, Goriya Y, Kajimoto Y, Shichiri M, Kamada T.

Diabetes Res Clin Pract. 1993 May;20(2):93-100.

PMID:
8375272
18.

The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized crossover trial.

Nimri R, Danne T, Kordonouri O, Atlas E, Bratina N, Biester T, Avbelj M, Miller S, Muller I, Phillip M, Battelino T.

Pediatr Diabetes. 2013 May;14(3):159-67. doi: 10.1111/pedi.12025. Epub 2013 Feb 28.

PMID:
23448393
19.

Intranasal glucagon in the treatment of hypoglycaemic attacks in children: experience at a summer camp.

Slama G, Reach G, Cahane M, Quetin C, Villanove-Robin F.

Diabetologia. 1992 Apr;35(4):398. No abstract available.

PMID:
1516770
20.

Supplemental Content

Support Center